Natco Pharma Regulatory Development & Financial Overview

Natco Pharma Ltd. has concluded a USFDA inspection at its Manali Active Pharmaceutical Ingredient (API) facility. 1. Regulatory Update: US FDA Inspection Event: The US FDA completed an inspection of the Manali API manufacturing unit in Chennai. Timeline: The inspection was conducted from November 17 to November 21, 2025. Outcome: The regulator issued seven Form 483 observations. Management Stance: The company has classified these observations as procedural in nature. Management has expressed confidence in comprehensively addressing these points and remains committed to strict adherence to Current Good Manufacturing Practice (cGMP) standards to ensure uninterrupted supply to global markets. 2. Market Reaction following the news, market sentiment showed mild caution. Stock Performance: Natco Pharma shares closed marginally lower by 0.84% at ₹862 on the NSE on Friday, November 21, 2025. 3. Q2 FY26 Financial Performance Context Investors should view the regulatory update against the backdrop of the recent earnings report for the quarter ending September 30, 2025 (Q2 FY26). Net Profit: Reported at ₹518 crore, reflecting a 23.5% decline YoY (compared to ₹677.3 crore in the previous fiscal). Revenue: Consolidated revenue slipped marginally to ₹1,363 crore. EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization fell 28% YoY to ₹579 crore. Margin Compression: The EBITDA margin contracted significantly to 42.5%, down from 58.6% in the corresponding quarter last year, indicating operational pressure. Dividend: An interim dividend of ₹1.50 per share has been declared for FY26. Investment Outlook While the issuance of seven Form 483 observations warrants monitoring, the procedural nature of the observations suggests a manageable remediation path. Investors will likely focus on the speed of the company's response to the FDA and its ability to stabilize margins in the coming quarters.